Cobalt-Based Drug Delivery to the Brain using Rapid Short-Pulses of Focused Ultrasound and Microbubbles reduces Aβ aggregation in 5XFAD mice
This study indicates that rapid short-pulse ultrasound can enhance the delivery of a cobalt-based therapeutic to reduce amyloid-β aggregation in a mouse model, but further research is needed to confirm these findings in humans.
Where it sits
this study against the rest of the snap-8 corpusSummary and findings
This study measured the effects of cobalt-based compound CoLAm2 on amyloid-β aggregation in 5xFAD mice using rapid short-pulse ultrasound. Mice received three weekly treatments of 5 mg/kg CoLAm2 alongside focused ultrasound. A 60.5% reduction in Aβ plaque area was observed with combined treatment compared to controls.
Abstract
<title>Abstract</title> <p>A major obstacle to effective Alzheimer’s disease therapy is the limited ability to deliver therapeutics across the blood-brain barrier. Focused ultrasound with microbubbles can transiently increase BBB permeability, and rapid short-pulse (RaSP) sequences have been shown to improve the safety and efficiency of this approach. Here, we investigated whether repeated RaSP-ultrasound treatments could deliver the cobalt-based compound CoLAm2, an inhibitor of amyloid-β (Aβ) oligomerization, to the brains of 5xFAD mice. Five-month-old mice received three weekly treatments consisting of intravenous CoLAm2 (5 mg/kg) and targeted BBB opening in the left hippocampus using RaSP ultrasound sequences. Immunohistochemistry demonstrated a 60.5% reduction in Aβ plaque area in mice receiving combined focused ultrasound and CoLAm2 compared with ultrasound-only, drug-only, and untreated controls. Ultrasound-only treatment also reduced aggregated Aβ by 35.6%, as assessed by Thioflavin S staining. Open field and novel object recognition tests detected no adverse effects on locomotor activity, anxiety-like behaviour, or cognition following repeated treatments. These findings demonstrate that repeated RaSP-ultrasound enables safe delivery of a small-molecule therapeutic across the BBB and enhances its anti-amyloid effects in a mouse model of Alzheimer’s disease, supporting further investigation of this approach for neurological disorders.</p>
Background
This study addresses the challenge of delivering drugs to the brain to reduce amyloid-beta (Aβ) aggregation, a key feature of Alzheimer's disease. Previous research has explored various methods to enhance drug delivery across the blood-brain barrier. This study's use of cobalt-based delivery with focused ultrasound and microbubbles may represent a novel approach.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Without access to the full study details, it is difficult to compare these findings to existing literature or assess their clinical significance. The use of 5XFAD mice suggests a preclinical focus, and the absence of human data limits immediate clinical applicability.
Key findings
- Not reported in abstract.
Limitations
- Abstract not available
- Mouse model only, no human data
- Preclinical focus
- Details on Snap-8's role not provided